Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Dave Moore, Novo Nordisk’s executive vice president of U.S. operations, discusses the drugmaker’s new once-a-day oral diet pill launched by the drugmaker on “The Claman Countdown.”
There is huge interest in Wegovy’s oral version of its injectable weight-loss drug, Dave Moore, head of Novo Nordisk, told FOX Business on Friday.
Wegovy’s one-dose pill, an oral spin-off of its injectable medication for weight losswas approved in December 2025 by the Food and Drug Administration as the first oral GLP-1 drug and launched in U.S. markets on Monday.
“There are so many patients who have been sitting on the sidelines waiting because they didn’t really see themselves being treated with an injection,” Moore, executive vice president of Novo Nordisk’s U.S. operations, said of “Claman’s countdown“Now that the pill is available, we’re seeing a lot of enthusiasm and a lot of activity.”
WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT
Wegovy injection pens laid out in Waterbury, Vermont on April 28, 2025. (Shelby Knowles/Bloomberg via Getty Images / Getty Images)
Drugmaker Novo Nordisk makes Wegovy. Moore told FOX Business that clinical trials show the pill provides similar weight loss results to the injection.
“There is not much difference,” explained the head of the drugmaker. “That’s why we’re so excited. That’s what we’re so proud of at Novo Nordisk, is that patients now don’t have to make choices. They don’t have to compromise.”
The pill will be available at 70,000 pharmacies across the country, including major retailers like CVS, Costco and Good Rx.
TARGETING BEEF FOR PROTEIN, ADDITIONAL OFFERS, CAPITALIZING ON WEIGHT LOSS DRUG TREND
Wegovy is marketed as a prescription injectable weight loss medication. (Michael Siluk/UCG/Universal Images Group via Getty Images / Getty Images)
The price of the semaglutide pill is lower than the injectable version for those who pay in cash. Eligible, insured customers will pay about $25 per month, while uninsured customers will pay $149 per month, FOX Business anchor Liz Claman reported.
Moore noted that the cost of manufacturing the pill and the injection was about the same for Novo Nordisk, but that making the pill affordable was a priority for the drugmaker.
Besides the lower price, he also highlighted the secondary benefits associated with Wegovy beyond weight loss.
“The injection and the pill have a secondary indication, which is to reduce the risk of cardiovascular disease,” Moore said.
The FDA classifies the drug as a heart disease preventative.
AMERICA’S OBESITY CRISIS MEETS OZEMPIC BOOM AS DATA REVEALS GLP-1 HOT SPOTS
Although Wegovy’s pill is the only FDA-approved oral GLP-1 medication for weight loss, Novo Nordisk’s rival Eli Lilly is reportedly close to being approved for oral version.
Eli Lilly headquarters in Indianapolis, Indiana on May 3, 2023. (AJ Mast/Bloomberg via Getty Images / Getty Images)
Moore also addressed concerns about what happens when patients stop taking GLP-1 medications, noting that many of them regain weight.
“If you stop treatment, it is likely that the weight will come back, and so prolonged treatment is important,” he said.
“Just like taking medication for hypertension or diabetes, long-term treatment is necessary,” Moore added.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Claman asked if Novo Nordisk was exploring alternatives that would not require lifetime use.
“There is a lot of R&D [research and development] it’s happening, and of course we’re at the center of that,” Moore said.
